DK3677271T3 - Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider - Google Patents

Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider Download PDF

Info

Publication number
DK3677271T3
DK3677271T3 DK19212541.7T DK19212541T DK3677271T3 DK 3677271 T3 DK3677271 T3 DK 3677271T3 DK 19212541 T DK19212541 T DK 19212541T DK 3677271 T3 DK3677271 T3 DK 3677271T3
Authority
DK
Denmark
Prior art keywords
supernatans
microvesicles
isolation
purification
procedure
Prior art date
Application number
DK19212541.7T
Other languages
Danish (da)
English (en)
Inventor
Evangelos V Badiavas
Arsalan Q Shabbir
Stephen C Davis
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of DK3677271T3 publication Critical patent/DK3677271T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983—Blood, e.g. plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
DK19212541.7T 2013-03-13 2014-03-12 Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider DK3677271T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778591P 2013-03-13 2013-03-13
EP14774189.6A EP2972193B1 (en) 2013-03-13 2014-03-12 Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids

Publications (1)

Publication Number Publication Date
DK3677271T3 true DK3677271T3 (da) 2023-05-22

Family

ID=51625222

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19212541.7T DK3677271T3 (da) 2013-03-13 2014-03-12 Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider
DK14774189.6T DK2972193T3 (da) 2013-03-13 2014-03-12 Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14774189.6T DK2972193T3 (da) 2013-03-13 2014-03-12 Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider

Country Status (13)

Country Link
US (3) US10500231B2 (enExample)
EP (3) EP2972193B1 (enExample)
JP (3) JP6562897B2 (enExample)
CN (2) CN105209881B (enExample)
AU (4) AU2014244618A1 (enExample)
CA (1) CA2906502A1 (enExample)
DK (2) DK3677271T3 (enExample)
ES (2) ES2778098T3 (enExample)
FI (1) FI3677271T3 (enExample)
HU (2) HUE049003T2 (enExample)
PL (2) PL2972193T3 (enExample)
PT (2) PT2972193T (enExample)
WO (1) WO2014159662A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10500231B2 (en) 2013-03-13 2019-12-10 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US20180325830A1 (en) 2017-05-09 2018-11-15 Vivex Biomedical, Inc. Coated biological composition
US11160904B2 (en) 2017-05-09 2021-11-02 Vivex Biologies Group, Inc. Biological composition in a protectant shroud and methods
US9687511B2 (en) * 2015-03-06 2017-06-27 Vivex Biomedical, Inc. Acellular biologic composition and method of manufacture
US10596123B2 (en) 2015-03-11 2020-03-24 Mayo Foundation For Medical Education And Research Exosome delivery technology
WO2016149358A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
WO2017023690A1 (en) * 2015-07-31 2017-02-09 Exoceuticals, Inc. Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair
KR102418785B1 (ko) * 2015-09-25 2022-07-08 (주)프로스테믹스 식물 착즙물 유래 세포 외 소포체를 포함하는 피부 개선 및 탈모 방지용 조성물
KR102475127B1 (ko) * 2015-09-30 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 포함하는 탈모 방지 또는 육모 촉진용 조성물
CN108883138A (zh) * 2015-12-30 2018-11-23 加利福利亚大学董事会 增强细胞衍生的囊泡的生产和分离的方法
US10463695B2 (en) * 2016-01-19 2019-11-05 Matti J. SIRÉN Methods and compositions for use in the prevention, treatment and/or alleviation of cancer
KR102475129B1 (ko) * 2016-03-22 2022-12-07 (주)아모레퍼시픽 인삼 유래의 엑소좀 유사 베지클을 유효성분으로 포함하는 항노화용 조성물
WO2018039100A2 (en) * 2016-08-23 2018-03-01 Albert Einstein College Of Medicine, Inc. Stem cell-produced microvesicles for treating tendon pathologies
EP3568143B1 (en) * 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
JP2020528766A (ja) * 2017-07-26 2020-10-01 ロゼッタ エクソソーム 陽イオンを利用した細胞外小胞体の分離方法
CN111183354B (zh) * 2017-07-27 2023-09-15 康奈尔大学 细胞外囊泡的固定和保留
KR102722950B1 (ko) * 2017-09-22 2024-10-28 더 유니버시티 오브 마이애미 수포성 표피박리증의 치료를 위한 방법 및 조성물
US11471559B2 (en) * 2017-11-20 2022-10-18 Vivex Biologics Group, Inc. Bioenergetic bone
WO2019148072A1 (en) * 2018-01-29 2019-08-01 Forever Labs, Inc. System and method for isolating extracellular vesicles
CN108414334A (zh) * 2018-02-23 2018-08-17 中山大学附属第医院 一种从精液中分离提纯外泌体的方法
AU2019343188A1 (en) 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
EP3930734A4 (en) * 2019-02-28 2022-12-07 Merakris Therapeutics, LLC EXTRACELLULAR VESICLES DERIVED FROM AMBIENT WATER AND THEIR USES IN WOUND HEALING
IT201900024580A1 (it) * 2019-12-18 2021-06-18 Consiglio Nazionale Ricerche Vescicole extracellulari da microalghe
CN113384597A (zh) * 2020-03-13 2021-09-14 西比曼生物科技（上海）有限公司 含人体细胞衍生的细胞膜外囊泡的雾化吸入制剂、制法及其应用
CN111893093A (zh) * 2020-08-03 2020-11-06 沈阳三禾生物科技有限公司 一种脐带间充质干细胞来源的超微因子的制备方法
WO2022040516A1 (en) 2020-08-21 2022-02-24 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP4230724A4 (en) * 2020-10-16 2024-05-22 FUJIFILM Corporation CULTURE MEDIUM FOR THE PRODUCTION OF EXTRACELLULAR VESICLES, CULTURE MEDIUM KIT, ADDITIVE AND METHOD FOR THE PRODUCTION OF EXTRACELLULAR VESICLES
CN114081900B (zh) * 2021-02-24 2024-11-22 济宁医学院附属医院 间充质干细胞来源的纳米微囊泡在制备治疗子痫前期的药物中的应用
CN115212230B (zh) * 2021-04-21 2024-12-27 时比曼生物科技(上海)有限公司 含有干细胞胞外囊泡的药物组合物及其在呼吸道炎症治疗中的应用
WO2023205158A1 (en) 2022-04-19 2023-10-26 University Of Miami Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease
KR20240028586A (ko) * 2022-08-24 2024-03-05 (주) 테라베스트 인간 세포 유래 미세소포체 및 히알루론산 또는 콜라겐을 포함하는 조성물 및 이의 용도
CN116898781B (zh) * 2023-02-07 2025-08-15 中国中医科学院中医基础理论研究所 大麦苗外泌体在制备具有抗衰老修护作用的产品中的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
CA2426654C (en) 2000-10-23 2010-12-21 Smithkline Beecham Corporation 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
EP1395652A2 (en) * 2000-11-30 2004-03-10 Stemron, Inc. Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
KR100519384B1 (ko) 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
EP1766053A4 (en) * 2004-06-02 2007-12-12 Sourcepharm Inc MICROVESICLES CONTAINING RNA AND METHODS
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
KR20070058441A (ko) 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
EP3517151B1 (en) 2006-03-09 2021-04-21 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
ES2442890T3 (es) 2006-07-13 2014-02-14 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon
EP1939218A1 (en) * 2006-12-29 2008-07-02 Thrombotargets Europe, S.L. Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
US7709010B2 (en) 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
US8216784B2 (en) 2007-07-25 2012-07-10 University Of Louisville Research Foundation, Inc. Cancer-derived microvesicle-associated microrna as a diagnostic marker
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
ES2409180T3 (es) * 2007-10-15 2013-06-25 Fresenius Medical Care Deutschland Gmbh Uso de microvesículas (MVS), para preparar un medicamento que tiene actividad de adyuvante en el trasplante de células endoteliales, particularmente en el tratamiento de la diabetes mediante el trasplante de islotes pancreáticos,y método relacionado
ES2523098T3 (es) * 2007-10-29 2014-11-20 Fresenius Medical Care Deutschland Gmbh Microvesícula (MV) derivada de células madre para su uso en la inhibición de la apoptosis inducida por un agente citostático
WO2009087361A1 (en) 2008-01-04 2009-07-16 Lydac Neuroscience Limited Microvesicles
US8617806B2 (en) 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
US20120058492A1 (en) 2008-01-25 2012-03-08 Hansabiomed Ou Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
DK2245199T3 (da) * 2008-02-01 2014-02-03 Gen Hospital Corp Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
CN102014934B (zh) * 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
MX2010011206A (es) * 2008-04-16 2010-11-12 Biogen Idec Inc Metodo para aislar biomacromoleculas usando glicol de polialquileno y metales de transicion.
US10545149B2 (en) 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
CA2744100C (en) 2008-10-21 2020-06-30 The General Hospital Corporation Cell transplantation
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
BRPI0900815A2 (pt) 2009-04-23 2010-12-28 Sociedade Benef Israelita Bras Hospital Albert Einstein método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro
CN107412755A (zh) 2009-07-02 2017-12-01 Ith免疫治疗控股公司 基于外泌体的癌症治疗
IN2012DN00866A (enExample) * 2009-07-16 2015-07-10 Gen Hospital Corp
US20120309041A1 (en) 2010-01-08 2012-12-06 Leonardus Timmers Determination of Exosomel Biomarkers for Predicting Cardiovascular Events
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2012002760A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
WO2012020307A2 (en) * 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Therapeutic uses of microvesicles and related micrornas
US20120053976A1 (en) 2010-08-31 2012-03-01 Xerox Corporation System and method for determining whether service costs can be reduced
US20120093885A1 (en) * 2010-10-18 2012-04-19 Northwestern University Therapeutic vesicles
US20130209528A1 (en) * 2010-10-18 2013-08-15 Agency For Science, Technology And Research Use of exosomes to promote or enhance hair growth
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2012110099A1 (en) 2011-02-18 2012-08-23 Cavadis B.V. Determination of exosomal biomarkers for predicting cardiovascular events
WO2012126531A1 (en) 2011-03-24 2012-09-27 Cavadis B.V. Method for diagnosing acute coronary syndrome (acs)
WO2012110253A2 (en) 2011-02-18 2012-08-23 Cavadis B.V. Exosomal biomarkers for cardiovascular events
US9816998B2 (en) 2011-04-01 2017-11-14 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
SG195306A1 (en) 2011-06-08 2013-12-30 Agency Science Tech & Res Purification of biological products by constrained cohydration chromatography
WO2013014669A1 (en) 2011-07-24 2013-01-31 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
CA2846211A1 (en) * 2011-08-05 2013-02-14 University Of Louisville Research Foundation, Inc. Microrna biomarkers
EP2604288A1 (en) 2011-12-16 2013-06-19 Biocant - Associação De Transferência De Tecnologia Nanoparticles and uses thereof
EP3245586A1 (de) 2011-12-23 2017-11-22 Appbyyou GmbH Verfahren zum aufbau einer verschlüsselten verbindung zwischen zwei kommunikationsgeräten nach vorherigem schlüsselaustausch über eine kurzstreckenverbindung
US20130273544A1 (en) 2012-04-17 2013-10-17 Life Technologies Corporation Methods and compositions for exosome isolation
WO2013188832A1 (en) * 2012-06-14 2013-12-19 System Biosciences, Llc Methods for microvesicle isolation and selective removal
US9005888B2 (en) 2012-06-14 2015-04-14 System Biosciences, Llc Methods for microvesicle isolation and selective removal
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
WO2014028493A2 (en) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
CN105051192B (zh) 2012-11-13 2020-04-17 科迪艾克生物科学公司 治疗剂的递送
US10500231B2 (en) 2013-03-13 2019-12-10 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US20180104186A1 (en) 2013-03-13 2018-04-19 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
SG11201601939VA (en) 2013-09-16 2016-04-28 Agency Science Tech & Res Method
WO2015138878A1 (en) 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
CN107106614A (zh) 2014-09-15 2017-08-29 新加坡科技研究局 用外泌体治疗移植物抗宿主病（gvhd）或大疱性表皮松解症（eb）的方法
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
HK1256111A1 (zh) 2016-01-12 2019-09-13 康干细胞生物技术有限公司 干细胞衍生的含有大量生长因子的外来体
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
KR102722950B1 (ko) 2017-09-22 2024-10-28 더 유니버시티 오브 마이애미 수포성 표피박리증의 치료를 위한 방법 및 조성물
WO2022040516A1 (en) 2020-08-21 2022-02-24 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells

Also Published As

Publication number Publication date
AU2022206811B2 (en) 2024-08-15
AU2014244618A1 (en) 2015-10-08
US12453745B2 (en) 2025-10-28
PT3677271T (pt) 2023-05-31
US20230364150A1 (en) 2023-11-16
JP2022084634A (ja) 2022-06-07
EP2972193B1 (en) 2019-12-18
ES2949637T3 (es) 2023-10-02
EP3677271B1 (en) 2023-04-19
JP7417301B2 (ja) 2024-01-18
FI3677271T3 (fi) 2023-06-06
EP4218774A1 (en) 2023-08-02
AU2020223723A1 (en) 2020-09-10
AU2018211351A1 (en) 2018-08-23
AU2022206811A1 (en) 2022-08-18
PL2972193T3 (pl) 2020-08-24
CN112795533A (zh) 2021-05-14
ES2778098T3 (es) 2020-08-07
CN105209881A (zh) 2015-12-30
EP2972193A4 (en) 2016-09-07
JP2019195331A (ja) 2019-11-14
US11730768B2 (en) 2023-08-22
JP6562897B2 (ja) 2019-08-21
US20200163999A1 (en) 2020-05-28
AU2018211351C1 (en) 2020-12-10
HUE049003T2 (hu) 2020-09-28
PL3677271T3 (pl) 2023-08-21
US10500231B2 (en) 2019-12-10
WO2014159662A1 (en) 2014-10-02
CN105209881B (zh) 2021-01-22
EP2972193A1 (en) 2016-01-20
DK2972193T3 (da) 2020-03-23
CA2906502A1 (en) 2014-10-02
AU2018211351B2 (en) 2020-05-28
EP3677271A1 (en) 2020-07-08
JP7405389B2 (ja) 2023-12-26
PT2972193T (pt) 2020-04-23
US20160184363A1 (en) 2016-06-30
JP2016518109A (ja) 2016-06-23
HUE062348T2 (hu) 2023-10-28

Similar Documents

Publication Publication Date Title
DK3677271T3 (da) Fremgangsmåde til isolering og oprensning af microvesikler fra cellekultur-supernatanter og biologiske fluider
DK2970872T3 (da) Mikroorganismer og fremgangsmåder til fremstilling af sialylerede og N-acetylglucosamin-holdige oligosaccharider
IL256525A (en) Taurine supplemented cell culture medium and methods of use
DK2855667T5 (da) Fremgangsmåder til manipulation af allogeniske og immunosuppressiv-resistante T-celler til immunterapi
DK2968415T3 (da) Cd123-specifik kimær antigenreceptor-omdirigerede t-celler og fremgangsmåder til anvendelse deraf
DK2919923T3 (da) Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2970890T3 (da) Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK2553113T3 (da) FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
DK2989470T3 (da) Indretning og fremgangsmåde til automatisk behandling af kulturplader til mikrobiologiske prøver
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK3399019T3 (da) Fremgangsmåder til bevaring af kulturs levedygtighed
DK2889365T3 (da) Fremgangsmåde til undersøgelse af mikroorganismer og indretning dertil
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK3080353T3 (da) Fremgangsmåde til oprensning og isolering af lignin
DK3150710T3 (da) Fremgangsmåde til fremstilling af homoserin-lacton og organisk syre fra mikroorganisme-afledt o-acyl-homoserin
DK3019452T3 (da) Fremgangsmåde for og installation af biologisk denitrifikation af spildevand
DK3060659T3 (da) Alfa-amylaser fra exiguobacterium og fremgangsmåder til anvendelse deraf
DK3434306T3 (da) Indretning til adskillelse af gas og fluid
DK2576033T3 (da) Apparat til gasning af flydende medier
DK3064574T3 (da) Fremgangsmåde til differentiering af pluripotente stamceller induceret fra mesenkymstamceller til chondrocyt